Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Merus N.V. MRUS NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • NL • USD

SharesGrow Score
44/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$110.00
+22.2%

Merus N.V. (MRUS) is a Biotechnology company in the Healthcare sector, currently trading at $90.00. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is MRUS = $110 (+22.2% upside).

Financials: revenue is $36M, -9.1%/yr average growth. Net income is $215M (loss), growing at -51.1%/yr. Net profit margin is -595.9% (negative). Gross margin is 100% (+175.7 pp trend).

Balance sheet: total debt is $10M against $648M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 6.54 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $785M.

Analyst outlook: 10 / 22 analysts rate MRUS as buy (45%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 46/100 (Partial), Income 10/100 (Fail).

$110.00
▲ 22.22% Upside
Average Price Target
The 12-month price target for Merus N.V. is $110.00.

MRUS SharesGrow Score Overview

51/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 46/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MRUS

✓
VALUE Pass
75/100
MRUS trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $110, implying +22.2% from the current price $90. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
MRUS: -9.1%/yr revenue is, -51.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet MRUS: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 6.54 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
MRUS: Gross margin is 100% (+175.7 pp trend), $7B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
46/100
Analyst outlook: 10 / 22 analysts rate MRUS as buy (45%). Analyst consensus target is $110 (+22.2% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
MRUS: Net profit margin is -595.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range33.19-97.14
Volume2.72M
Avg Volume (30D)1.72M
Market Cap$6.83B
Beta (1Y)1.06
Share Statistics
EPS (TTM)-3.35
Shares Outstanding$64.22M
IPO Date2016-05-19
Employees260
CEOJan van de Winkel
Financial Highlights & Ratios
Revenue (TTM)$36.13M
Gross Profit$36.13M
EBITDA$-269.6M
Net Income$-215.33M
Operating Income$-272.07M
Total Cash$537.03M
Total Debt$9.91M
Net Debt$-283.38M
Total Assets$785.13M
Price / Earnings (P/E)-26.9
Price / Sales (P/S)188.91
Analyst Forecast
1Y Price Target$110.00
Target High$110.00
Target Low$110.00
Upside+22.2%
Rating ConsensusHold
Analysts Covering22
Buy 45% Hold 55% Sell 0%
Price Target Summary
Company Info
CountryNL
ExchangeNASDAQ Global Market
CurrencyUSD
ISINNL0011606264

Price Chart

Track all markets on TradingView
MRUS
Merus N.V. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
33.19 52WK RANGE 97.14

People Also View

PCVX
PCVX
Vaxcyte, Inc.
$62.76
+1.64%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 CRNX
CRNX
Crinetics Pharmaceuticals, Inc.
$39.75
+2.82%
 SNDX
SNDX
Syndax Pharmaceuticals, Inc.
$24.43
+0.74%
 ANAB
ANAB
AnaptysBio, Inc.
$70.22
+2.17%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 INBX
INBX
Inhibrx Biosciences, Inc.
$83.19
+7.40%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message